[1] LUTZ T A. Control of food intake and energy expenditure by amylin-therapeutic implications.[J]. International Journal of Obesity, 2009, 33 Suppl 1: S24-7. DOI:
10.1038/ijo.2009.13[2] C M MACK. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight[J]. International Journal of Obesity, 2009, 34 2: 385-395. DOI:
10.1038/ijo.2009.238[3] A M GÓMEZ-FOIX J J G J E Rodriguez Gil. Anti-insulin effects of amylin and calcitonin-gene-related peptide on hepatic glycogen metabolism.[J]. Biochemical Journal, 1991, 276 ( Pt 3): 607-610. DOI:
10.1042/bj2760607[4] WILLIAM VINE. Comparison of the in vitro and in vivo pharmacology of adrenomedullin, calcitonin gene-related peptide and amylin in rats[J]. European journal of pharmacology, 1996, 314 1: Pages 115-121. DOI:
10.1016/s0014-2999(96)00544-4[5] G CHRISTOPOULOS. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product.[J]. Molecular Pharmacology, 1999, 56 1: 235-242. DOI:
10.1124/mol.56.1.235[6] JANELLE GREEN . Full-length Rat Amylin Forms Fibrils Following Substitution of Single Residues from Human Amylin[J]. Journal of Molecular Biology, 2003, 326 4: Pages 1147-1156. DOI:
10.1016/s0022-2836(02)01377-3